QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer (NCT06551116)
🩺 Plain-English Summary (8th-Grade Level)
This study will assess whether a quantitative, HER2 assay can accurately and reliably discriminate between responders and non-responders among patients with HER2 IHCI+ metastatic breast cancer who are receiving T-Dxd.
Who can join: Review the eligibility criteria below.
Location: University of California San Francisco Medical Center — San Francisco, California
Age range: 18 Years
🧪 Interventions in This Study
- CE-10-IVD (DIAGNOSTIC_TEST)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (37 Sites)
Showing the first 25 of 37 sites.
- University of California San Francisco Medical Center — San Francisco, California
- Smilow Cancer Hospital-Derby Care Center — Derby, Connecticut
- Smilow Cancer Hospital Care Center — Fairfield, Connecticut
- Smilow Cancer Hospital at Glastonbury — Glastonbury, Connecticut
- Smilow Cancer Hospital Care Center at Greenwich — Greenwich, Connecticut
- Smilow Cancer Hospital Care Center — Guilford, Connecticut
- Smilow Cancer Hospital at Saint Francis — Hartford, Connecticut
- Yale-New Haven Hospital North Haven Medical Center — New Haven, Connecticut
- Yale Cancer Center — New Haven, Connecticut
- Smilow Cancer Hospital Care Center at Long Ridge — Stamford, Connecticut
- Smilow Cancer Hospital-Torrington Care Center — Torrington, Connecticut
- Smilow Cancer Hospital Care Center — Trumbull, Connecticut
- Smilow Cancer Hospital-Waterbury Care Center — Waterbury, Connecticut
- Smilow Cancer Hospital Care Center - Waterford — Waterford, Connecticut
- Georgetown University - Lombardi CCC — Washington D.C., District of Columbia
- MedStar Washington Hospital Center — Washington D.C., District of Columbia
- Sibley Memorial Hospital — Washington D.C., District of Columbia
- University of Chicago Medical Center — Chicago, Illinois
- University of Chicago Comprehensive Cancer Center at Silver Cross — New Lenox, Illinois
- University of Chicago Medicine-Orland Park — Orland Park, Illinois
- University of Chicago Medicine Northwest Indiana — Crown Point, Indiana
- John's Hopkins Hospital — Baltimore, Maryland
- Penn Medicine Princeton Medical Center — Plainsboro, New Jersey
- Montefiore Einstein Medical Center — The Bronx, New York
- UNC Chapel Hill — Chapel Hill, North Carolina
📞 Contact the Study Coordinator
Phone: (215) 908-2599
Email: angela.demichele@pennmedicine.upenn.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in HER2-positive Metastatic Breast Cancer
Explore by condition: All HER2-positive Metastatic Breast Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.